TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06788639: A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06788639 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06788639 Rescue Dossier →